H. pylori
Conditions
Interventions
stool samples group:None
gastric fluid group:None
gastric mucosa group:None
Sponsors
Civil Aviation General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Select 18-75 years (including thresholds at both ends), no gender limitation; 2) patients with 14C or 13C breath test positive for H. pylori; 3) patients who have not eradicated H pylori within the last six months; 4) subjects have fully understood the study and voluntarily signed a written informed consent.
Exclusion criteria
Exclusion criteria: 1) Those who have used proton pump inhibitors or H2 receptor antagonists, antibiotics, bismuth agents, and gastric mucosal protectors within 4 weeks before screening; 2) Previous repeated use (5 times or more times in 1 year) or long-term use (continuous use for 10 weeks or more) macrolide and penicillin drugs; 3) For the trial-related drugs, Such as bismuth agent, rabeprazole, penicillin (amoxicillin, etc.), macrolide (clarithromycin, etc.), levofloxacin, metronidazole in any component allergy or test-related drug contraindications; 4) Patients with malignant tumors or a history of esophageal and gastrointestinal surgery; 5) Patients with pyloric obstruction, gastric perforation, esophageal erosion, ulcer, esophagitis, and Zhuo-Ai syndrome; 6) Patients with acute upper gastrointestinal bleeding within the previous week before screening; 7) Drugs or NSAIDs affecting the anticoagulation system, coagulation system and fibrinolytic system are required during the trial; 8) other serious cardiac, liver and renal insufficiency, anemia and other severe hematopoietic and coagulation diseases are not effectively controlled; 9) pregnant or lactating women, or subjects with positive pregnancy examination, or birth planning within 6 months after screening examination; 10) a history of drug or alcohol abuse within 1 year before screening, or do not agree to the provisions of the trial during the study; 11) the investigator comprehensively determine that patients who are not suitable for the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| consistency of H. pylori drug resistance gene testing ; | — |
Secondary
| Measure | Time frame |
|---|---|
| sensitivity;specificity; | — |
Countries
China
Contacts
Public ContactJianping Cheng
Civil Aviation General Hospital
Outcome results
None listed